BioCryst Pharmaceuticals BCRX Current maturities of long-term debt
Current maturities of long-term debt at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's current maturities of long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's current maturities of long-term debt?
- BioCryst Pharmaceuticals (BCRX) reported current maturities of long-term debt of $1.24M in Q1 2026.
- How has BioCryst Pharmaceuticals's current maturities of long-term debt changed year-over-year?
- BioCryst Pharmaceuticals's current maturities of long-term debt decreased by 31.2% year-over-year, from $1.8M to $1.24M.
- What is the long-term trend for BioCryst Pharmaceuticals's current maturities of long-term debt?
- Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's current maturities of long-term debt has grown at a 2.7% compound annual growth rate (CAGR), from $1.18M to $1.31M.